Molecular Assemblies, Inc.
Acquired
Matched to this startup by its exact name; the buyer's report is the source.
| Acquired | Buyer | Acquisition date | Completion | Price | Stake | Source |
|---|---|---|---|---|---|---|
| Molecular Assemblies, Inc | Maravai LifeSciences Holdings, Inc. | 2025 | — | $11 M | — | Annual report |
Funding rounds
3 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Sep 2021 | $26 M | No. 3 | $10 to $50 million | equity | SEC | |
| Sep 2019 | $14 M | No. 2 | $10 to $50 million | equity | SEC | |
| Sep 2016 | $6 M | No. 1 | $2 to $10 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Molecular Assemblies, Inc. chose not to state its revenue in its newest notice of a funding round (Sep 2022).
SEC Form D · Sep 2022
The industry group it chose in its notices: Biotechnology.
SEC Form D · Sep 2022
That is all the official record says: Molecular Assemblies, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).
Investors#
No investor of Molecular Assemblies, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 36 investors.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| J. William Efcavitch, Ph.D. | Treasurer and Chief Scientific Officer | Sep 2022 |
| Michael J. Kamdar | President, Chief Executive Officer and Secretary | Sep 2022 |
| Sean William Freeman | Secretary | Oct 2019 |
| Curt William Becker | Secretary, CFO and Chief Commercial Officer | Aug 2017 |
| Helge William Bastian | Director | Sep 2022 |
| J. William Efcavitch, Ph.D. | Treasurer and Chief Scientific Officer | Sep 2022 |
| Jeffrey William Sampson, Ph.D. | Director | Sep 2022 |
| John William Nicols | Director | Sep 2022 |
| Larry William Stambaugh | Chairman of the Board of Directors | Sep 2022 |
| Michael J. Kamdar | President, Chief Executive Officer and Secretary | Sep 2022 |
| Todd William Peterson | Director | Sep 2022 |
| David William Hwang | Director | Sep 2021 |
| David H. Hwang | Director | Oct 2019 |
| Helge H. Bastian | Director | Oct 2019 |
| Joe H. Smith | Director | Oct 2019 |
| Larry H. Stambaugh | Chairman of the Board of Directors | Oct 2019 |
| Sean William Freeman | Secretary | Oct 2019 |
| Curt William Becker | Secretary, CFO and Chief Commercial Officer | Aug 2017 |
Acquired (Jan 1, 2025). Acquired by Maravai LifeSciences Holdings, Inc..